Theralase Technologies (TSE:TLT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theralase Technologies has opened a new clinical study site at St. Joseph’s Healthcare Hamilton in Canada to advance its promising anti-cancer therapy for bladder cancer. The Phase II study has shown that over 68% of treated patients achieved a positive response, highlighting the potential of Theralase’s innovative treatment approach. This progress offers hope for the significant number of bladder cancer patients diagnosed annually in North America.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
